Rare Kidney Diseases Market: Industry Trends and Global Forecasts, Till 2040

The global rare kidney diseases market size is valued at USD 2.2 billion in 2024 and is projected to reach USD 2.8 billion in the current year and USD 11. 6 billion by 2035, growing at a CAGR of 15.2% during the forecast period.

Rare Kidney Diseases Market: Growth and Trends

Kidney illnesses encompass various disorders that impair the kidneys' natural function of effectively filtering waste and surplus fluid from the bloodstream. These ailments also affect the kidneys' ability to control blood pressure and sustain the body's fluid balance. Importantly, in the initial phases, kidney disorders frequently show no signs, complicating the diagnosis. Nonetheless, as toxins build up in the body, individuals might encounter symptoms such as elevated blood pressure, anemia, inadequate nutritional health, and nerve injury. As per the US Centers for Disease Control and Prevention, around 35.5 million individuals in the US are projected to be impacted by kidney diseases in the recent year, representing nearly 14% of the total population. A portion of these conditions, infrequent kidney disorders, impact a smaller percentage of people globally. According to the Orphan Drug Act, a condition is considered rare in the US if it impacts fewer than 200,000 individuals. In the European Union, rare diseases are characterized as affecting approximately 5 out of every 10,000 Europeans.

Rare kidney disorders mainly impact the filtering units of the kidneys (referred to as glomeruli), resulting in the leakage of protein elements and blood into the urine. These conditions may be congenital, acquired, or inherited, which complicates the identification of specific biomarkers for diagnosis and treatment. In the absence of effective treatment methods, rare kidney disorders frequently result in kidney failure, requiring dialysis or organ transplant. It is notable that kidney failure stemming from a rare chronic kidney disease has been seen in at least 3 of 5 children and 1 in 9 adults affected by kidney diseases. To tackle these issues, considerable progress has been achieved in identifying and managing rare kidney disorders. Precision treatments, such as genomic analysis and tailored therapies, have facilitated the focused management of these conditions. Further, the incorporation of big data and machine learning has aided numerous drug developers and researchers by enhancing patient recruitment for clinical trials and identifying precise urinary biomarkers for personalized treatment.

Additionally, significant funding from both public and private sectors speeds up research and development in this area. Currently, pharmaceutical companies have obtained more than USD 12 billion in financing for research and treatment advancements for rare kidney conditions. Moreover, as there is an increasing emphasis on effective diagnosis and treatment, the market for therapies and drugs for rare kidney diseases is set for substantial growth, offering considerable opportunities for stakeholders in the years ahead.

Rare Kidney Diseases Market: Key Insights

The report delves into the current state of the rare kidney diseases market and identifies potential growth opportunities within the industry. Some key findings from the report include:

Over 70% of the rare kidney drugs / therapies are in clinical stages of development; notably, most of the drugs / therapies are being investigated for the treatment of immunoglobulin A nephropathy and lupus nephritis.

The rising interest in this domain is evident from the wide array of partnerships established between various stakeholders in the recent past; in fact, 65% of the total deals were inked in the last three years.

Several investors, having realized the opportunity within this domain, have invested significant capital across various funding rounds; 45% of the investments in this domain were made through secondary offerings.
Nearly 40% of the drugs targeting rare kidney diseases are currently in Phase II of clinical development; notably, around 60% of the trials have been sponsored by industry players.
The rare kidney disease market is likely to grow at an annualized rate (CAGR) of 15.2%, till 2035; the majority of the market share (~70%) is expected to be captured by North America by 2035.

Currently, the monoclonal antibodies dominate the market; notably, oral route of administration is anticipated to capture the majority share in the market by 2035.

Rare Kidney Diseases Market: Key Segments

Lupus Nephritis is the Fastest Growing Segment in the Rare Kidney Diseases Market

In terms of the type of target disease indication, the global rare kidney disease market is segmented into atypical hemolytic uremic syndrome, Fabry disease, focal segmental glomerulosclerosis, immunoglobulin A nephropathy, lupus nephritis, and others. Currently, lupus nephritis holds the largest portion of the rare kidney disease market, owing to the growing awareness of the disease's severity among both patients and healthcare providers.

Small Molecules are Likely to Hold the Largest Share of the Rare Kidney Diseases Market During the Forecast Period

In terms of the type of molecule, the global market is segmented into small molecules and biologics. Within these categories, the small molecules segment holds the largest portion of the current market. However, it is important to note that biologics are projected to develop into a viable option that can address the fundamental biological mechanisms linked rare kidney diseases, thus obtaining a greater market share in the near future.

Rare Kidney Diseases Market for Proteins is Likely to Grow at a Relatively Faster Pace During the Forecast Period

Based on the type of biologic, the global market value is segmented across enzymes, hormones, monoclonal antibodies, and proteins. Notably, the monoclonal antibodies segment dominates the current market. Moreover, this trend is unlikely to change in the foreseen future owing to their proven precision in treating rare kidney diseases.

Oral Route of Administration Holds the Largest Share of the Rare Kidney Diseases Market

Based on the route of administration, the global market is segmented across intravenous, oral and subcutaneous routes of administration. Currently, the oral route is expected to hold the majority rare kidney disease market share owing to its non-invasive nature and increased patient compliance as compared to other routes. However, it is worth mentioning that this trend is expected to change during the forecast period, with the subcutaneous route of administration capturing a larger share of the overall market in the coming years.

By Type of Therapy, Monotherapy Segment is Likely to Dominate the Market During the Forecast Period

Based on the type of therapy, the global market for rare kidney diseases is segmented across monotherapy and combination therapy. At present, the monotherapy segment holds the maximum share in the overall market. However, the market for combination therapy is likely to grow at a relatively higher CAGR during the forecast period.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, and Asia-Pacific. In the current scenario, North America is likely to capture the largest market share. However, the Asia-Pacific market is anticipated to expand more quickly during the forecast period due to rising incidence rates of rare kidney diseases in several Asian countries, including China, Japan, Korea, and India, which require improved treatment management systems in these countries.

Example Players in the Rare Kidney Diseases Market

Alexion Pharmaceuticals
Amicus Therapeutics
Apellis Pharmaceuticals
Aurinia Pharmaceuticals
GlaxoSmithKline
Novartis
Roche
Travere Therapeutics
Vera Therapeutics

Rare Kidney Diseases Market: Research Coverage

The report on rare kidney diseases market features insights into various sections, including:

Market Sizing and Opportunity Analysis: An in-depth analysis of the rare kidney diseases market, focusing on key market segments, including [A] type of disease indication, [B] type of molecule, [C] type of biologic, [D] route of administration, [E] type of therapy, [F] key geographical regions, and [G] key players.
Market Landscape: A comprehensive evaluation of rare kidney diseases drugs / therapies developers, based on several relevant parameters, such as [A] stage of development, [B] target indication, [C] route of administration, [D] type of molecule, [E] type of biologic, [F] dosing frequency, [G] target patient population, and [H] type of therapy.
Rare Kidney Diseases Drug / Therapies Developer Landscape: The report features a list of leading players engaged in the rare kidney diseases domain, along with analyses based on [A] year of establishment, [B] company size, [C] location of headquarters, and [D] most active players (in terms of number of drugs / therapies developed).
Company Competitiveness Analysis: An insightful competitiveness analysis of the companies engaged in the rare kidney diseases domain, based on various relevant parameters, such as [A] company strength, [B] portfolio strength, and [C] pipeline diversity.
Company Profiles: In-depth profiles of key industry players offering rare kidney drugs / therapies across various geographies, focusing on [A] company overviews, [B] drug portfolio, [C] financial information (if available), [D] recent developments and [E] an informed future outlook.
Partnerships and Collaborations: A detailed analysis of partnerships inked between stakeholders in the rare kidney diseases market, since 2019, based on several relevant parameters, such as [A] year of partnership, [B] type of partnership, [C] target disease indication, [D] type of partner, [E] most active players (in terms of number of partnerships), and [F] geography.
Funding and Investments Analysis: A detailed analysis of the various funding and investments raised in the rare kidney diseases domain, based on several relevant parameters, such as [A] year of funding, [B] type of funding, [C] amount of funding, [D] target disease indication, [E] geography, and [F] most active players (in terms of number of funding instances).
Clinical Trial Analysis: An in-depth analysis of completed / ongoing clinical trials related to rare kidney diseases drugs / therapies, based on various relevant parameters, such as [A] trial registration year, [B] trial status, [C] number of patients enrolled, [D] trial phase, [E] study design (type of trial masking, type of intervention model, trial purpose and design allocation), [F] type of sponsor, [G] patient gender, [H] most active sponsor / collaborator (leading industry and non-industry players based on the number of registered trials), and [I] geography.
Clinical Commercial Attractiveness: A detailed analysis of the clinical and commercial attractiveness for phase III drugs / therapies targeting rare kidney diseases, based on several parameters, such as [A] type of molecule, [B] dosing frequency, [C] route of administration, [D] number of patients enrolled, [E] company size, [F] patient population, and [G] location of clinical trials.
KOL Analysis: An insightful analysis, highlighting the key opinion leaders investigating the clinical trials related to rare kidney diseases, based on several parameters, such as [A] type of KOL, [B] qualification, [C] type of organization, [D] geographical location of KOLs, [E] target disease indication, and [F] most prominent KOLs (based on our proprietary and third-party scoring criteria).
Case Study: An insightful case study highlighting the developers engaged in offering kidney care services, along with information on [A] year of establishment, [B] company size, [C] location of headquarters, [D] target indications, [E] benefits offered by the kidney care companies, and [F] recent developments in the domain.
Market Impact Analysis: A thorough analysis of various factors, such as drivers, restraints, opportunities, and existing challenges that are likely to impact market growth.

Key Questions Answered in this Report

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?
What is the patent filing activity trend in the market?

Reasons to Buy this Report

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

Complimentary Excel Data Packs
15% Free Content Customization
Detailed Report Walkthrough Session with the Research Team
Free Update if the Report is 6+ Months Old

SECTION I: REPORT OVERVIEW

1. BACKGROUND

1.1. Context
1.2. Project Objectives

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS

3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion

SECTION II: QUALITATIVE INSIGHTS5. EXECUTIVE SUMMARY

6. INTRODUCTION

6.1. Overview of Kidney Diseases
6.1.1. Key Historical Events related to Kidney Diseases
6.1.2. Factors Contributing to the Onset of Kidney Diseases
6.2. Selection of Therapeutic Targets for Rare Kidney Diseases
6.3. Technological Advancements in the Rare Kidney Diseases Domain
6.4. Recent Developments in the Rare Kidney Diseases Domain
6.5. Future Perspectives

SECTION III: COMPETITIVE LANDSCAPE

7. MARKET LANDSCAPE

7.1. Rare Kidney Disease Drugs / Therapies: Market Landscape
7.1.1. Analysis by Stage of Development
7.1.2. Analysis by Target Indication
7.1.3. Analysis by Route of Administration
7.1.4. Analysis by Type of Molecule
7.1.5. Analysis by Type of Biologic
7.1.6. Analysis by Dosing Frequency
7.1.7. Analysis by Target Patient Population
7.1.8. Analysis by Type of Therapy
7.2. Rare Kidney Disease Drugs / Therapies: Developer Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Company Size and Location of Headquarters
7.2.5. Most Active Players: Analysis by Number of Drugs / Therapies Developed

8. COMPANY COMPETITIVENESS ANALYSIS

8.1 Methodology and Key Parameters
8.2. Scoring
8.3. Peer Groups
8.3.1. Overview of Developers based in North America
8.3.1.1. Competitiveness Analysis of Players based in North America
8.3.1.2. Leading Players based in North America
8.3.2. Overview of Developers based in Europe
8.3.2.1. Competitiveness Analysis of Players based in Europe
8.3.2.2. Leading Players based in Europe
8.3.3. Overview of Developers based in Asia-Pacific and Rest of the World
8.3.3.1. Competitiveness Analysis of Players based in Asia-Pacific and Rest of the World
8.3.3.2. Leading Players based in Asia-Pacific and Rest of the World

SECTION IV: COMPANY PROFILES

9. RARE KIDNEY DISEASE MARKET: COMPANY PROFILES OF DRUG / THERAPY DEVELOPERS BASED IN NORTH AMERICA

9.1. Chapter Overview
9.2. Alexion Pharmaceuticals
9.2.1. Company Details
9.2.2. Drug Portfolio
9.2.3. Financial Details
9.2.4. Recent Developments and Future Outlook
9.3. Biogen
9.3.1. Company Details
9.3.2. Drug Portfolio
9.3.3. Financial Details
9.3.4. Recent Developments and Future Outlook
9.4. NovelMed
9.4.1. Company Details
9.4.2. Drug Portfolio
9.4.3. Recent Developments and Future Outlook
9.5. Travere Therapeutics
9.5.1. Company Details
9.5.2. Drug Portfolio
9.5.3. Financial Details
9.5.4. Recent Developments and Future Outlook
9.6. Vertex Pharmaceuticals
9.6.1. Company Details
9.6.2. Drug Portfolio
9.6.3. Financial Details
9.6.4. Recent Developments and Future Outlook
9.7. Amgen
9.7.1. Company Details
9.7.2. Drug Portfolio
9.8. Vera Therapeutics
9.8.1. Company Details
9.8.2. Drug Portfolio
9.9. ZyVersa Therapeutics
9.9.1. Company Details
9.9.2. Drug Portfolio

10. RARE KIDNEY DISEASE MARKET: COMPANY PROFILES OF DRUG / THERAPY DEVELOPERS BASED IN EUROPE

10.1. Chapter Overview
10.2. Novartis
10.2.1. Company Details
10.2.2. Drug Portfolio
10.2.3. Financial Details
10.2.4. Recent Developments and Future Outlook
10.3. Roche
10.3.1. Company Details
10.3.2. Drug Portfolio
10.3.3. Financial Details
10.3.4. Recent Developments and Future Outlook
10.4. Advicenne
10.4.1. Company Details
10.4.2. Drug Portfolio
10.5. Boehringer Ingelheim
10.5.1. Company Details
10.5.2. Drug Portfolio
10.6. Calliditas Therapeutics
10.6.1. Company Details
10.6.2. Drug Portfolio

11. RARE KIDNEY DISEASE MARKET: COMPANY PROFILES OF DRUG / THERAPY DEVELOPERS BASED IN ASIA-PACIFIC

11.1. Chapter Overview
11.2. Jiangsu Hengrui Pharmaceuticals
11.2.1. Company Details
11.2.2. Drug Portfolio
11.2.3. Recent Developments and Future Outlook
11.2. Asahi Kasei
11.2.1. Company Details
11.2.2. Drug Portfolio

SECTION V: MARKET TRENDS

12. PARTNERSHIPS AND COLLABORATIONS

12.1. Partnership Models
12.2. Rare Kidney Disease Drugs / Therapies: Partnerships and Collaborations
12.2.1. Analysis by Year of Partnership
12.2.2. Analysis by Type of Partnership
12.2.3. Analysis by Year and Type of Partnership
12.2.4. Analysis by Target Disease Indication
12.2.5. Analysis by Type of Partner
12.2.6. Most Active Players: Analysis by Number of Partnerships
12.2.7. Local and International Deals
12.2.8. Intercontinental and Intracontinental Deals

13. FUNDING AND INVESTMENTS

13.1. Funding Models
13.2. Funding Lifecycle Analysis
13.3. Investment Case: Risk and Return
13.4. Rare Kidney Disease Drugs / Therapies: Funding and Investments
13.4.1. Analysis of Funding Instances by Year of Funding
13.4.2. Analysis of Funding Instances by Type of Funding
13.4.3. Analysis of Funding Instances by Year and Type of Funding
13.4.4. Analysis of Amount Invested by Year of Funding
13.4.5. Analysis of Amount Invested by Type of Funding
13.4.6. Analysis of Amount Invested by Year and Type of Funding
13.4.7. Analysis of Funding Instances by Target Disease Indication
13.4.8. Analysis of Funding Instances by Geography (Region)
13.4.9. Analysis of Funding Instances by Geography (Country)
13.4.10. Most Active Players: Analysis by Number of Funding Instances
13.4.11. Most Active Players: Analysis by Amount Invested
13.4.12. Leading Investors: Analysis by Number of Funding Instances
13.5. Summary of Investments

14. CLINICAL TRIAL ANALYSIS

14.1. Methodology and Key Parameters
14.2. Rare Kidney Disease Drugs / Therapies: Clinical Trial Analysis
14.2.1. Analysis by Trial Registration Year
14.2.2. Analysis by Trial Status
14.2.3. Analysis by Trial Registration Year and Trial Status
14.2.4. Analysis by Trial Registration Year and Patients Enrolled
14.2.5. Analysis by Trial Status and Patients Enrolled
14.2.6. Analysis by Trial Phase
14.2.7. Analysis by Patients Enrolled and Trial Phase
14.2.8. Analysis by Study Design
14.2.9. Analysis by Type of Sponsor
14.2.10. Analysis by Patient Gender
14.2.11. Most Active Industry Players: Analysis by Number of Trials
14.2.12. Most Active Non-Industry Players: Analysis by Number of Trials
14.2.13. Analysis by Geography
14.2.13.1. Analysis by Trial Status, Trial Phase and Geography
14.2.13.2. Analysis by Trial Status and Geography
14.2.14. Geographical Distribution of Trials and Number of Patients Enrolled
14.2.14.1. Clinical Trials in North America: Key Insights
14.2.14.2. Clinical Trials in Europe: Key Insights
14.2.14.3. Clinical Trials in Asia-Pacific: Key Insights
14.2.14.4. Clinical Trials in Rest of the World: Key Insights

15. CLINICAL COMMERCIAL ATTRACTIVENESS

15.1. Methodology and Key Parameters
15.2. Scoring
15.3. Phase III Drugs / Therapies Targeting Rare Kidney Diseases

16. KEY OPINION LEADERS

16.1. Methodology and Key Parameters
16.2. Rare Kidney Disease Drugs / Therapies: Key Opinion Leaders
16.2.1. Analysis by Type of Key Opinion Leader
16.2.2. Analysis by Qualification
16.2.3. Analysis by Type of Organization
16.2.4. Analysis by Target Disease Indication
16.2.5. Analysis by Region of Key Opinion Leaders
16.3. Scoring Criteria
16.3.1. Most Prominent Key Opinion Leaders
16.3.2. Benchmarking: Roots Analysis’ Assessment vs Third Party Scores

17. RARE KIDNEY DISEASE MARKET: CASE STUDY

17.1. Methodology
17.2. Rare Kidney Disease Market: List of Kidney Care Companies
17.3. Benefits Offered by Kidney Care Companies
17.4. Recent Developments

SECTION VI: MARKET FORECAST AND OPPORTUNITY ANALYSIS

18. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

18.1. Chapter Overview
18.2. Market Drivers
18.3. Market Restraints
18.4. Market Opportunities
18.5. Market Challenges
18.6. Conclusion

19. RARE KIDNEY DISEASE MARKET

19.1. Key Assumptions and Methodology
19.2. Global Rare Kidney Disease Market: Historical Trends and Forecasted Estimates, till 2040
19.2.1. Comparison with Previous Edition
19.2.2. Multivariate Scenario Analysis
19.2.2.1. Conservative Scenario
19.2.2.2. Optimistic Scenario
19.3. Key Market Segmentations

20. RARE KIDNEY DISEASE MARKET, BY TARGET DISEASE INDICATION

20.1. Rare Kidney Disease Market: Distribution by Target Disease Indication
20.1.1. Rare Kidney Disease Market for Lupus Nephritis: Historical Trends and Forecasted Estimates, till 2040
20.1.2. Rare Kidney Disease Market for Immunoglobulin A Nephropathy: Historical Trends and Forecasted Estimates, till 2040
20.1.3. Rare Kidney Disease Market for Fabry Disease: Historical Trends and Forecasted Estimates, till 2040
20.1.4. Rare Kidney Disease Market for Atypical Hemolytic Uremic Syndrome: Historical Trends and Forecasted Estimates, till 2040
20.1.5. Rare Kidney Disease Market for Focal Segmental Glomerulosclerosis: Historical Trends and Forecasted Estimates, till 2040
20.1.6. Rare Kidney Disease Market for Others: Historical Trends and Forecasted Estimates, till 2040

21. RARE KIDNEY DISEASE MARKET, BY TYPE OF MOLECULE

21.1. Rare Kidney Disease Market: Distribution by Type of Molecule
21.1.1. Rare Kidney Disease Market for Small Molecules: Historical Trends and Forecasted Estimates, till 2040
21.1.2. Rare Kidney Disease Market for Biologics: Historical Trends and Forecasted Estimates, till 2040

22. RARE KIDNEY DISEASE MARKET, BY TYPE OF BIOLOGIC

22.1. Rare Kidney Disease Market: Distribution by Type of Biologic
22.1.1. Rare Kidney Disease Market for Monoclonal Antibodies: Historical Trends and Forecasted Estimates, till 2040
22.1.2. Rare Kidney Disease Market for Enzymes: Historical Trends and Forecasted Estimates, till 2040
22.1.3. Rare Kidney Disease Market for Proteins: Historical Trends and Forecasted Estimates, till 2040
22.1.4. Rare Kidney Disease Market for Hormones: Historical Trends and Forecasted Estimates, till 2040

23. RARE KIDNEY DISEASE MARKET, BY ROUTE OF ADMINISTRATION

23.1. Rare Kidney Disease Market: Distribution by Route of Administration
23.1.1. Rare Kidney Disease Market for Oral Route: Historical Trends and Forecasted Estimates, till 2040
23.1.2. Rare Kidney Disease Market for Intravenous Route: Historical Trends and Forecasted Estimates, till 2040
23.1.3. Rare Kidney Disease Market for Subcutaneous Route: Historical Trends and Forecasted Estimates, till 2040

24. RARE KIDNEY DISEASE MARKET, BY TYPE OF THERAPY

24.1. Rare Kidney Disease Market: Distribution by Type of Therapy
24.1.1. Rare Kidney Disease Market for Monotherapy: Historical Trends and Forecasted Estimates, till 2040
24.1.2. Rare Kidney Disease Market for Combination Therapy: Historical Trends and Forecasted Estimates, till 2040

25. RARE KIDNEY DISEASE MARKET, BY KEY GEOGRAPHICAL REGIONS

25.1. Rare Kidney Disease Market: Distribution by Key Geographical Regions
25.1.1. Rare Kidney Disease Market in North America: Historical Trends and Forecasted Estimates, till 2040
25.1.1.1. Rare Kidney Disease Market in the US: Historical Trends and Forecasted Estimates, till 2040
25.1.1.2. Rare Kidney Disease Market in Canada: Historical Trends and Forecasted Estimates, till 2040
25.1.2. Rare Kidney Disease Market in Europe: Historical Trends and Forecasted Estimates, till 2040
25.1.2.1. Rare Kidney Disease Market in Germany: Historical Trends and Forecasted Estimates, till 2040
25.1.2.2. Rare Kidney Disease Market in UK: Historical Trends and Forecasted Estimates, till 2040
25.1.2.3. Rare Kidney Disease Market in Spain: Historical Trends and Forecasted Estimates, till 2040
25.1.2.4. Rare Kidney Disease Market in France: Historical Trends and Forecasted Estimates, till 2040
25.1.2.5. Rare Kidney Disease Market in the Italy: Historical Trends and Forecasted Estimates, till 2040
25.1.3. Rare Kidney Disease Market in Asia-Pacific: Historical Trends and Forecasted Estimates, till 2040
25.1.3.1. Rare Kidney Disease Market in China: Historical Trends and Forecasted Estimates, till 2040
25.1.3.2. Rare Kidney Disease Market in India: Historical Trends and Forecasted Estimates, till 2040
25.1.3.3. Rare Kidney Disease Market in South Korea: Historical Trends and Forecasted Estimates, till 2040
25.1.3.4. Rare Kidney Disease Market in Japan: Historical Trends and Forecasted Estimates, till 2040
25.1.3.5. Rare Kidney Disease Market in Australia: Historical Trends and Forecasted Estimates, till 2040
25.1.3.6. Rare Kidney Disease Market in Taiwan: Historical Trends and Forecasted Estimates, till 2040

26. RARE KIDNEY DISEASE MARKET, SALES FORECAST OF DRUGS

26.1. Approved Rare Kidney Disease Drugs / Therapies: Sales Forecast
26.1.1. Benlysta®: Sales Forecast
26.1.2. Elfabrio®: Sales Forecast
26.1.3. FILSPARI®: Sales Forecast
26.1.4. Galafold®: Sales Forecast
26.1.5. LUPKYNIS®: Sales Forecast
26.1.6. Sibnayal®: Sales Forecast
26.1.7. Tarpeyo®: Sales Forecast
26.1.8. TERLIVAZ®: Sales Forecast
26.1.9. ULTOMIRIS®: Sales Forecast
26.2. Phase III Rare Kidney Disease Drugs / Therapies: Sales Forecast
26.2.1. ALPN-303 (Immunoglobulin A Nephropathy): Sales Forecast
26.2.2. APL-2 (C3 Glomerulopathy): Sales Forecast
26.2.3. APL-2 (Membranous Nephropathy): Sales Forecast
26.2.4. Atacicept (Immunoglobulin A Nephropathy): Sales Forecast
26.2.5. Atacicept (Lupus Nephritis): Sales Forecast
26.2.6. Atrasentan (Immunoglobulin A Nephropathy): Sales Forecast
26.2.7. Crovalimab (Atypical Hemolytic Uremic Syndrome): Sales Forecast
26.2.8. FILSPARI® (Focal Segmental Glomerulosclerosis): Sales Forecast
26.2.9. Ianalumab (Lupus Nephritis): Sales Forecast
26.2.10. Iptacopan (Atypical Hemolytic Uremic Syndrome): Sales Forecast
26.2.11. Iptacopan (C3 Glomerulopathy): Sales Forecast
26.2.12. Iptacopan (Immunoglobulin A Nephropathy): Sales Forecast
26.2.13. Lucerastat (Fabry Disease): Sales Forecast
26.2.14. MIL62 (Membranous Nephropathy): Sales Forecast
26.2.15. Obinutuzumab (Nephrotic Syndrome): Sales Forecast
26.2.16. Obinutuzumab (Membranous Nephropathy): Sales Forecast
26.2.17. Obinutuzumab (Lupus Nephritis): Sales Forecast
26.2.18. Repagermanium (Focal Segmental Glomerulosclerosis): Sales Forecast
26.2.19. Saphnelo™ (Lupus Nephritis): Sales Forecast
26.2.20. Sibeprenlimab (Immunoglobulin A Nephropathy): Sales Forecast
26.2.21. SNP-ACTH (Membranous Nephropathy): Sales Forecast
26.2.22. Telitacicept (Immunoglobulin A Nephropathy): Sales Forecast
26.2.23. Tolvaptan (Autosomal Recessive Polycystic Kidney Disease): Sales Forecast
26.2.24. ULTOMIRIS® (Immunoglobulin A Nephropathy): Sales Forecast
26.2.25. Venglustat (Fabry Disease): Sales Forecast
26.2.26. Zigakibart (Immunoglobulin A Nephropathy): Sales Forecast

27. RARE KIDNEY DISEASE MARKET, BY LEADING DRUG DEVELOPERSSECTION VII: OTHER EXCLUSIVE INSIGHTS28. CONCLUDING INSIGHTS29. INSIGHTS FROM PRIMARY RESEARCHSECTION VIII: APPENDICES30. TABULATED DATA31. LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 3.3 Market Dynamics: Example List of Parameters
Figure 4.1 Historical Analysis of Past Recessions and Lessons Learnt
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Key Historical Events related to Rare Kidney Diseases
Figure 6.2 Factors Contributing to the Onset of Kidney Diseases
Figure 6.3 Examples of Rare Kidney Diseases
Figure 6.4 Challenges Related to Diagnosis and Treatment of Rare Kidney Diseases
Figure 6.5 Selection of Therapeutic Targets for Rare Kidney Diseases
Figure 6.6 Technological Advancements in the Rare Kidney Diseases Domain
Figure 7.1 Rare Kidney Disease Drugs / Therapies: Distribution by Stage of Development
Figure 7.2 Rare Kidney Disease Drugs / Therapies: Distribution by Target Indication
Figure 7.3 Rare Kidney Disease Drugs / Therapies: Distribution by Route of Administration
Figure 7.4 Rare Kidney Disease Drugs / Therapies: Distribution by Type of Molecule
Figure 7.5 Rare Kidney Disease Drugs / Therapies: Distribution by Type of Biologic
Figure 7.6 Rare Kidney Disease Drugs / Therapies: Distribution by Dosing Frequency
Figure 7.7 Rare Kidney Disease Drugs / Therapies: Distribution by Target Patient Population
Figure 7.8 Rare Kidney Disease Drugs / Therapies: Distribution by Type of Therapy
Figure 7.9 Rare Kidney Disease Drug / Therapy Developers: Distribution by Year of Establishment
Figure 7.10 Rare Kidney Disease Drug / Therapy Developers: Distribution by Company Size
Figure 7.11 Rare Kidney Disease Drug / Therapy Developers: Distribution by Location of Headquarters
Figure 7.12 Rare Kidney Disease Drug / Therapy Developers: Distribution by Company Size and Location of Headquarters
Figure 7.13 Most Active Players: Analysis by Number of Drugs / Therapies Developed
Figure 8.1 Rare Kidney Disease Drug / Therapies Developers based in North America: Distribution by Company Size
Figure 8.2 Rare Kidney Disease Drug / Therapies Developers based in North America: Distribution by Stage of Development
Figure 8.3 Rare Kidney Disease Drug / Therapies Developers based in North America: Distribution by Type of Molecule
Figure 8.4 Competitive Analysis of Players based in North America
Figure 8.5 Rare Kidney Disease Drug / Therapies Developers based in Europe: Distribution by Company Size
Figure 8.6 Rare Kidney Disease Drug / Therapies Developers based in Europe: Distribution by Type of Molecule
Figure 8.7 Rare Kidney Disease Drug / Therapies Developers based in Europe: Distribution by Route of Administration
Figure 8.8 Competitive Analysis of Players based in Europe
Figure 8.9 Rare Kidney Disease Drug / Therapies Developers based in Asia-Pacific and Rest of the World: Distribution by Company Size
Figure 8.10 Rare Kidney Disease Drug / Therapies Developers based in Asia-Pacific and Rest of the World: Distribution by Stage of Development
Figure 8.11 Rare Kidney Disease Drug / Therapies Developers based in Asia-Pacific and Rest of the World: Distribution by Type of Molecule
Figure 8.12 Competitive Analysis of Players based in Asia-Pacific and Rest of the World
Figure 9.1 Alexion Pharmaceuticals: Annual Revenues, Since FY 2021 (USD Billion)
Figure 9.2 Biogen: Annual Revenues, Since FY 2021 (USD Billion)
Figure 9.3 Travere Therapeutics: Annual Revenues, Since FY 2021 (USD Million)
Figure 9.4 Vertex Pharmaceuticals: Annual Revenues, Since FY 2021 (USD Billion)
Figure 10.1 Novartis: Annual Revenues, Since FY 2021 (USD Billion)
Figure 10.2 Roche: Annual Revenues, Since FY 2021 (CHF Billion)
Figure 12.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 12.4 Partnerships and Collaborations: Distribution by Target Disease Indication
Figure 12.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 12.6 Most Active Players: Distribution by Number of Partnerships
Figure 12.7 Partnerships and Collaborations: Local and International Deals
Figure 12.8 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 12.9 Partnerships and Collaborations: Recent Examples
Figure 13.1 Funding and Investments: Funding Lifecycle Analysis
Figure 13.2 Funding and Investments: Distribution of Funding Instances by Year of Funding
Figure 13.3 Funding and Investments: Distribution of Funding Instances by Type of Funding
Figure 13.4 Funding and Investments: Distribution of Funding Instances by Year and Type of Funding
Figure 13.5 Funding and Investments: Distribution of Amount Invested by Year of Funding
Figure 13.6 Funding and Investments: Distribution of Amount Invested by Type of Funding
Figure 13.7 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding
Figure 13.8 Funding and Investments: Distribution of Funding Instances by Target Disease Indication
Figure 13.9 Funding and Investments: Distribution of Funding Instances by Geography (Region)
Figure 13.10 Funding and Investments: Distribution of Funding Instances by Geography (Country)
Figure 13.11 Most Active Players: Distribution by Number of Instances
Figure 13.12 Most Active Players: Distribution by Amount Invested
Figure 13.13 Leading Investors: Distribution by Number of Funding Instances
Figure 13.14 Funding and Investments: Summary
Figure 14.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 14.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 14.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 14.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Figure 14.5 Clinical Trial Analysis: Distribution by Trial Status and Patients Enrolled
Figure 14.6 Clinical Trial Analysis: Distribution by Trial Phase
Figure 14.7 Clinical Trial Analysis: Distribution by Patients Enrolled and Trial Phase
Figure 14.8 Clinical Trial Analysis: Distribution by Study Design
Figure 14.9 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 14.10 Clinical Trial Analysis: Distribution by Gender
Figure 14.11 Most Active Industry Players: Distribution by Number of Trials
Figure 14.12 Most Active Non-Industry Players: Distribution by Number of Trials
Figure 14.13 Distribution by Trial Status, Trial Phase and Geography
Figure 14.14 Distribution of Clinical Trials by Trial Status and Geography
Figure 14.15 Distribution of Patients Enrolled by Trial Status and Geography
Figure 14.16 Geographical Distribution of Trials and Number of Patients Enrolled
Figure 14.17 Clinical Trials in North America: Key Insights
Figure 14.18 Clinical Trials in Europe: Key Insights
Figure 14.19 Clinical Trials in Asia-Pacific: Key Insights
Figure 14.20 Clinical Trials in Rest of the World: Key Insights
Figure 15.1 Phase III Drugs / Therapies Targeting Rare Kidney Diseases
Figure 16.1 Rare Kidney Disease Drugs / Therapies KOL Analysis: Distribution by Type of KOL
Figure 16.2 Rare Kidney Disease Drugs / Therapies KOL Analysis: Distribution by Qualification
Figure 16.3 Rare Kidney Disease Drugs / Therapies KOL Analysis: Distribution by Type of Organization
Figure 16.4 Rare Kidney Disease Drugs / Therapies KOL Analysis: Distribution by Target Disease Indication
Figure 16.5 Rare Kidney Disease Drugs / Therapies KOL Analysis: Distribution by Geographical Location
Figure 16.6 Most Prominent Key Opinion Leaders
Figure 16.7 Benchmarking: Roots Analysis’ Assessment vs Third Party Scores
Figure 17.1 Benefits Offered by Kidney Care Companies
Figure 19.1 Rare Kidney Disease Market, Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 19.2 Global Rare Kidney Disease Market, Historical Trends and Forecasted Estimates, till 2040: Conservative Scenario (USD Billion)
Figure 19.3 Global Rare Kidney Disease Market, Historical Trends and Forecasted Estimates, till 2040: Optimistic Scenario (USD Billion)
Figure 20.1 Rare Kidney Disease Market: Distribution by Target Disease Indication
Figure 20.2 Rare Kidney Disease Market for Lupus Nephritis: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 20.3 Rare Kidney Disease Market for Immunoglobulin A Nephropathy: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 20.4 Rare Kidney Disease Market for Fabry Disease: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 20.5 Rare Kidney Disease Market for Atypical Hemolytic Uremic Syndrome: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 20.6 Rare Kidney Disease Market for Focal Segmental Glomerulosclerosis: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 20.7 Rare Kidney Disease Market for Others: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 21.1 Rare Kidney Disease Market: Distribution by Type of Molecule
Figure 21.2 Rare Kidney Disease Market for Small Molecules: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 21.3 Rare Kidney Disease Market for Biologics: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 22.1 Rare Kidney Disease Market: Distribution by Type of Biologic
Figure 22.2 Rare Kidney Disease Market for Monoclonal Antibodies: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 22.3 Rare Kidney Disease Market for Enzymes: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 22.4 Rare Kidney Disease Market for Proteins: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 22.5 Rare Kidney Disease Market for Hormones: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 23.1 Rare Kidney Disease Market: Distribution by Route of Administration
Figure 23.2 Rare Kidney Disease Market for Oral Route: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 23.3 Rare Kidney Disease Market for Intravenous Route: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 23.4 Rare Kidney Disease Market for Subcutaneous Route: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 24.1 Rare Kidney Disease Market: Distribution by Type of Therapy
Figure 24.2 Rare Kidney Disease Market for Monotherapy: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 24.3 Rare Kidney Disease Market for Combination Therapy: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 25.1 Rare Kidney Disease Market: Distribution by Key Geographical Regions
Figure 25.2 Rare Kidney Disease Market in North America: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 25.3 Rare Kidney Disease Market in the US: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 25.4 Rare Kidney Disease Market in Canada: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 25.5 Rare Kidney Disease Market in Europe: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 25.6 Rare Kidney Disease Market in Germany: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 25.7 Rare Kidney Disease Market in UK: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 25.8 Rare Kidney Disease Market in Spain: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 25.9 Rare Kidney Disease Market in France: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 25.10 Rare Kidney Disease Market in Italy: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 25.11 Rare Kidney Disease Market in Asia-Pacific: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 25.12 Rare Kidney Disease Market in China: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 25.13 Rare Kidney Disease Market in India: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 25.14 Rare Kidney Disease Market in South Korea: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 25.15 Rare Kidney Disease Market in Japan: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 25.16 Rare Kidney Disease Market in Australia: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 25.17 Rare Kidney Disease Market in Taiwan: Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
Figure 26.1 Benlysta®(Lupus Nephritis): Sales Forecast (USD Million)
Figure 26.2 Elfabrio®(Fabry Disease): Sales Forecast (USD Million)
Figure 26.3 FILSPARI®(Immunoglobulin A Nephropathy): Sales Forecast (USD Million)
Figure 26.4 FABHALTA® (Immunoglobulin A Nephropathy): Sales Forecast (USD Million)
Figure 26.5 Galafold®(Fabry Disease): Sales Forecast (USD Million)
Figure 26.6 LUPKYNIS®(Lupus Nephritis): Sales Forecast (USD Million)
Figure 26.7 Sibnayal® (Distal Renal Tubular Acidosis): Sales Forecast (USD Million)
Figure 26.8 Tarpeyo® (Immunoglobulin A Nephropathy): Sales Forecast (USD Million)
Figure 26.9 TERLIVAZ® (Hepatorenal Syndrome): Sales Forecast (USD Million)
Figure 26.10 ULTOMIRIS®(Atypical Hemolytic Uremic Syndrome): Sales Forecast (USD Million)
Figure 26.11 ALPN-303 (Immunoglobulin A Nephropathy): Sales Forecast (USD Million)
Figure 26.12 APL-2 (C3 Glomerulopathy): Sales Forecast (USD Million)
Figure 26.13 APL-2 (Membranous Nephropathy): Sales Forecast (USD Million)
Figure 26.14 Atacicept (Immunoglobulin A Nephropathy): Sales Forecast (USD Million)
Figure 26.15 Atacicept (Lupus Nephritis): Sales Forecast (USD Million)
Figure 26.16 Atrasentan (Immunoglobulin A Nephropathy): Sales Forecast (USD Million)
Figure 26.17 Crovalimab (Atypical Hemolytic Uremic Syndrome): Sales Forecast (USD Million)
Figure 26.18 FILSPARI® (Focal Segmental Glomerulosclerosis): Sales Forecast (USD Million)
Figure 26.19 Ianalumab (Lupus Nephritis): Sales Forecast (USD Million)
Figure 26.20 Iptacopan (Atypical Hemolytic Uremic Syndrome): Sales Forecast (USD Million)
Figure 26.21 Iptacopan (C3 Glomerulopathy): Sales Forecast (USD Million)
Figure 26.22 Lucerastat (Fabry Disease): Sales Forecast (USD Million)
Figure 26.23 MIL62 (Membranous Nephropathy): Sales Forecast (USD Million)
Figure 26.24 Obinutuzumab (Nephrotic Syndrome): Sales Forecast (USD Million)
Figure 26.25 Obinutuzumab (Membranous Nephropathy): Sales Forecast (USD Million)
Figure 26.26 Obinutuzumab (Lupus Nephritis): Sales Forecast (USD Million)
Figure 26.27 Repagermanium (Focal Segmental Glomerulosclerosis): Sales Forecast (USD Million)
Figure 26.28 Saphnelo™ (Lupus Nephritis): Sales Forecast (USD Million)
Figure 26.29 Sibeprenlimab (Immunoglobulin A Nephropathy): Sales Forecast (USD Million)
Figure 26.30 SNP-ACTH (Membranous Nephropathy): Sales Forecast (USD Million)
Figure 26.31 Telitacicept (Immunoglobulin A Nephropathy): Sales Forecast (USD Million)
Figure 26.32 Tolvaptan (Autosomal Recessive Polycystic Kidney Disease): Sales Forecast (USD Million)
Figure 26.33 ULTOMIRIS® (Immunoglobulin A Nephropathy): Sales Forecast (USD Million)
Figure 26.34 Venglustat (Fabry Disease): Sales Forecast (USD Million)
Figure 26.35 Zigakibart (Immunoglobulin A Nephropathy): Sales Forecast (USD Million)
Figure 26.36 Rare Kidney Disease Market: Distribution by Leading Players, 2025 (based on revenues generated) (USD Billion)
Figure 26.37 Rare Kidney Disease Market: Distribution by Leading Players, 2035 (based on revenues generated) (USD Billion)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

4D Molecular Therapeutics
5AM Ventures
AbbVie
Abingworth
AceLink Therapeutics
ACELYRIN
Achillion Pharmaceuticals
Adage Capital Management
Aduro Biotech
ADVANZ PHARMA
Advicenne
Alexandria Biotech
Alexion Pharmaceuticals (a subsidiary of AstraZeneca)
Alpine Immune Sciences
Alrov
Amgen
Amicus Therapeutics
Amyndas Pharmaceuticals
Annexon Biosciences
Apellis Pharmaceuticals
APIE Therapeutics
ARCH Venture Partners
argenx
Arrowhead Pharmaceuticals
Artiva Biotherapeutics
ARYA Sciences Acquisition Corp IV
Asahi Kasei
Astellas Pharma
AstraZeneca
Athyrium Capital Management
Aurinia Pharmaceuticals
Avanzanite
Bain Capital Life Sciences
Bayer
BeiGene
BioCity Biopharma
Biocon
Biogen
Biohaven
Birch Therapeutics
Blackstone
BNP Paribas
Boehringer Ingelheim
Boxer Capital
BPI France
Bristol-Myers Squibb
Cabaletta Bio
California Institute for Regenerative Medicine (CIRM)
Calliditas Therapeutics
CANbridge Life Sciences
Catalent
Cellares
CellGenTech
Cerium Pharmaceuticals
Certa Therapeutics
ChemoCentryx
Chiesi Farmaceutici
Chimagen Biosciences
Chinook Therapeutics
Children's Hospital of Zhejiang University School of Medicine
Chugai Pharmaceutical (a subsidiary of Roche)
Climb Bio
Codexis
Columbia University
Cormorant Capital
CSL
DARUI Biopharma
Deep Track Capital
Deerfield Management
Dimerix
Elaiapharm
Eleva
ElevateBio
Eloxx Pharmaceuticals
ENYO Pharma
Equillium
European Investment Bank
Everest Medicines
Evotec
ExCEEd Orphan
Exegenesis Bio
Fortress Biotech
Frazier Healthcare Partners
FrostPharma
GC Biopharma
Generium
Genpharm Services
Gilead Sciences
GlaxoSmithKline
Goldfinch Bio
GordonMD Global Investments
Guangdong Academy of Medical Sciences
Hanmi Pharmaceutical
Hansoh Pharmaceutical
Hayfin Capital Management
HI-Bio
Highbridge Capital
Hillhouse Capital
IASO Biotherapeutics
Idorsia Pharmaceuticals
IgA Nephropathy Foundation
ImmPACT Bio (a subsidiary of Lyell Immunopharma)
Inmunova
Ionis Pharmaceuticals
Janchor Partners
Janus Henderson Investors
JCR Pharmaceuticals
Jiangsu Hengrui Pharmaceuticals
Jiangsu Ruiyuan Biotechnology
Just - Evotec Biologics (a subsidiary of Evotec)
Keymed Biosciences
Kezar Life Sciences
Kira Pharmaceuticals
Komodo Health
Kyorin Pharmaceutical
Kyverna Therapeutics
Lake Bleu Capital
Lilly Asia Ventures
LogicBio Therapeutics
Lonza
Lupus Therapeutics
M6P Therapeutics
MAB WORKS
Mallinckrodt Pharmaceuticals
Medical Research Future Fund
Medison Pharma
Medpace
Merck
Monograph Capital
More Investment House
Morehouse School of Medicine
Morningside Ventures
MorphoSys
Nacuity Pharmaceuticals
Nagoya University
Nanjing Drum Tower Hospital
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health
NephCure
Nkarta
Northpond Ventures
Novartis
NovelMed
OccuRx
Ocelot Bio
Omeros
ONO Pharmaceutical
Oraxion Therapeutics (a spin-off of Aten Porus Lifesciences)
OrbiMed
Otsuka Pharmaceutical
Oxford Biomedica
Papillon Therapeutics
Peking Union Medical College Hospital
Pfizer
Pivotal bioVenture Partners
Pontifax
Protalix Biotherapeutics
Psagot Investment House
Q32 Bio
RA Capital Management
Recordati Rare Diseases
Redmile Group
RemeGen Biosciences
Renalys Pharma
River Renal
Roche
ROHTO Pharmaceutical
Rona Therapeutics
Rosalind Capital
Samsara BioCapital
Sangamo Therapeutics
Sanofi
SCOHIA PHARMA
Selexis
Shanghai Pharmaceuticals
Shanghai Shengdi Pharmaceutical
Skyline Therapeutics
Società Prodotti Antibiotici
STADA Arzneimittel
Sumitomo Dainippon Pharma
SVB Leerink
Swedish Orphan Biovitrum
SynAct Pharma
Synlogic
Taiba Healthcare
Takeda
Tenet Medicines
TJ Biopharma
Travere Therapeutics (formerly known as Retrophin Therapeutics)
Truveta
TwinPharma
UBS
UCB Ventures
uniQure
University of Michigan
venBio Partners
Venrock Healthcare Capital Partners
Vera Therapeutics
Verily
Versant Ventures
Vertex Pharmaceuticals
Viatris
Vida Ventures
Viking Global Investors
Visterra (a subsidiary of Otsuka Pharmaceutical)
Vivo Capital
Walden Biosciences
Westlake Village BioPartners
WuXi Advanced Therapies
WuXi Biologics
Zai Lab
ZyVersa Therapeutics (formerly known as Variant Pharmaceuticals)

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a single user license, allowing one user access to the product.	€4253EUR$4,799USD£3,690GBP
SITE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6202EUR$6,999USD£5,382GBP
ENTERPRISE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is an enterprise license, allowing all employees within your organization access to the product.	€15950EUR$17,999USD£13,841GBP